Epidemiology and Etiology of Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome and Goodpasture Syndrome: Vasculitides with Frequent Lung Involvement

 

 Buy Article Permissions and Reprints

ABSTRACT

This review focuses on the epidemiological characteristics and etiologies of four primary systemic vasculitides with frequent lung involvement, namely Wegener granulomatosis (WG), microscopic polyangiitis (MPA), Churg-Strauss syndrome (CSS), and Goodpasture syndrome (GPS). Elucidation of the mechanisms underlying these vasculitides with frequent lung involvement is complicated by their rarity, which hampers the undertaking of large-scale studies; difficulties in classification; and their multifaceted clinical presentations, which infer the existence of several etiologic pathways. Notwithstanding, epidemiological research showed some evidence for international, interethnic, and temporal variations of the frequencies of these four vasculitides; led to the identification of several genetic and environmental risk factors; and provided insight on the extent to which genes and environment might contribute to their development. Available data support the concept that WG, MPA, CSS, and GPS have unique and shared risk determinants. Although the precise causes of these vasculitides are not yet fully understood and the development of prevention strategies is out of our reach at present, current knowledge enables the formulation of etiologic hypotheses to provide caregivers and their patients with valuable information on the nature of these rare entities.

REFERENCES

• 1 Jennette J C, Falk R J. Small-vessel vasculitis.  N Engl J Med. 1997;  337 (21) 1512-1523
  CrossrefPubMedGoogle Scholar
• 2 Savage C O, Harper L, Adu D. Primary systemic vasculitis.  Lancet. 1997;  349 (9051) 553-558
  CrossrefPubMedGoogle Scholar
• 3 Carruthers D M, Watts R A, Symmons D P, Scott D G. Wegener's granulomatosis—increased incidence or increased recognition?.  Br J Rheumatol. 1996;  35 (2) 142-145
  CrossrefPubMedGoogle Scholar
• 4 Watts R A, Carruthers D M, Scott D G. Epidemiology of systemic vasculitis: changing incidence or definition?.  Semin Arthritis Rheum. 1995;  25 (1) 28-34
  CrossrefPubMedGoogle Scholar
• 5 Cotch M F, Hoffman G S, Yerg D E, Kaufman G I, Targonski P, Kaslow R A. The epidemiology of Wegener's granulomatosis: estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources.  Arthritis Rheum. 1996;  39 (1) 87-92
  CrossrefPubMedGoogle Scholar
• 6 Dadoniene J, Kirdaite G, Mackiewicz Z, Rimkevicius A, Haugeberg G. Incidence of primary systemic vasculitides in Vilnius: a university hospital population based study.  Ann Rheum Dis. 2005;  64 (2) 335-336
  CrossrefPubMedGoogle Scholar
• 7 González-Gay M A, García-Porrúa C. Systemic vasculitis in adults in northwestern Spain, 1988-1997: clinical and epidemiologic aspects.  Medicine (Baltimore). 1999;  78 (5) 292-308
  CrossrefPubMedGoogle Scholar
• 8 Gibson A, Stamp L K, Chapman P T, O'Donnell J L. The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region.  Rheumatology (Oxford). 2006;  45 (5) 624-628
  CrossrefPubMedGoogle Scholar
• 9 Gonzalez-Gay M A, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions.  Arthritis Rheum. 2003;  49 (3) 388-393
  CrossrefPubMedGoogle Scholar
• 10 Haugeberg G, Bie R, Bendvold A, Larsen A S, Johnsen V. Primary vasculitis in a Norwegian community hospital: a retrospective study.  Clin Rheumatol. 1998;  17 (5) 364-368
  CrossrefPubMedGoogle Scholar
• 11 Hissaria P, Cai F Z, Ahern M, Smith M, Gillis D, Roberts-Thomson P. Wegener's granulomatosis: epidemiological and clinical features in a South Australian study.  Intern Med J. 2008;  38 (10) 776-780
  CrossrefPubMedGoogle Scholar
• 12 Knight A, Ekbom A, Brandt L, Askling J. Increasing incidence of Wegener's granulomatosis in Sweden, 1975-2001.  J Rheumatol. 2006;  33 (10) 2060-2063
  PubMedGoogle Scholar
• 13 Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway.  Arthritis Rheum. 2000;  43 (11) 2481-2487
  CrossrefPubMedGoogle Scholar
• 14 Mohammad A J, Jacobsson L T, Mahr A D, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden.  Rheumatology (Oxford). 2007;  46 (8) 1329-1337
  CrossrefPubMedGoogle Scholar
• 15 Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate.  Arthritis Rheum. 2004;  51 (1) 92-99
  CrossrefPubMedGoogle Scholar
• 16 Mohammad A J, Jacobsson L T, Westman K W, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa.  Rheumatology (Oxford). 2009;  48 (12) 1560-1565
  CrossrefPubMedGoogle Scholar
• 17 Ormerod A S, Cook M C. Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales.  Intern Med J. 2008;  38 (11) 816-823
  CrossrefPubMedGoogle Scholar
• 18 Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross W L. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register.  Arthritis Rheum. 2005;  53 (1) 93-99
  CrossrefPubMedGoogle Scholar
• 19 Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R et al.. No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register.  Rheumatology (Oxford). 2002;  41 (5) 540-549
  CrossrefPubMedGoogle Scholar
• 20 Reinhold-Keller E, Zeidler A, Gutfleisch J, Peter H H, Raspe H H, Gross W L. Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany.  Rheumatology (Oxford). 2000;  39 (12) 1396-1402
  CrossrefPubMedGoogle Scholar
• 21 Takala J H, Kautiainen H, Malmberg H, Leirisalo-Repo M. Incidence of Wegener's granulomatosis in Finland 1981-2000.  Clin Exp Rheumatol. 2008;  26 (3, suppl 49) S81-S85
  PubMedGoogle Scholar
• 22 Watts R A, Al-Taiar A, Scott D G, Macgregor A J. Prevalence and incidence of Wegener's granulomatosis in the UK general practice research database.  Arthritis Rheum. 2009;  61 (10) 1412-1416
  CrossrefPubMedGoogle Scholar
• 23 Watts R A, Lane S E, Bentham G, Scott D G. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom.  Arthritis Rheum. 2000;  43 (2) 414-419
  CrossrefPubMedGoogle Scholar
• 24 Salama A D, Levy J B, Lightstone L, Pusey C D. Goodpasture's disease.  Lancet. 2001;  358 (9285) 917-920
  CrossrefPubMedGoogle Scholar
• 25 Bolton W K. Goodpasture's syndrome.  Kidney Int. 1996;  50 (5) 1753-1766
  CrossrefPubMedGoogle Scholar
• 26 Brisson M, Edmunds W J, Law B et al.. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom.  Epidemiol Infect. 2001;  127 (2) 305-314
  CrossrefPubMedGoogle Scholar
• 27 Lane S E, Watts R A, Bentham G, Innes N J, Scott D G. Are environmental factors important in primary systemic vasculitis? A case-control study.  Arthritis Rheum. 2003;  48 (3) 814-823
  CrossrefPubMedGoogle Scholar
• 28 Shah M K, Hugghins S Y. Characteristics and outcomes of patients with Goodpasture's syndrome.  South Med J. 2002;  95 (12) 1411-1418
  PubMedGoogle Scholar
• 29 O'Donnell J L, Stevanovic V R, Frampton C, Stamp L K, Chapman P T. Wegener's granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient.  Intern Med J. 2007;  37 (4) 242-246
  CrossrefPubMedGoogle Scholar
• 30 Gatenby P A, Lucas R M, Engelsen O, Ponsonby A L, Clements M. Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation?.  Arthritis Rheum. 2009;  61 (10) 1417-1424
  CrossrefPubMedGoogle Scholar
• 31 Watts R A, Lane S E, Scott D G et al.. Epidemiology of vasculitis in Europe.  Ann Rheum Dis. 2001;  60 (12) 1156-1157
  CrossrefPubMedGoogle Scholar
• 32 Kamali S, Erer B, Artim-Esen B et al.. Predictors of damage and survival in patients with Wegener's granulomatosis: analysis of 50 patients.  J Rheumatol. 2010;  37 (2) 374-378
  CrossrefPubMedGoogle Scholar
• 33 Cisternas M, Soto L, Jacobelli S Grupo de estudio de las vasculitis, Sociedad Chilena de Reumatología et al. Clinical features of Wegener granulomatosis and microscopic polyangiitis in Chilean patients [in Spanish].  Rev Med Chil. 2005;  133 (3) 273-278
  PubMedGoogle Scholar
• 34 Oh M J, Lee J Y, Kwon N H, Choi D C. Churg-Strauss syndrome: the clinical features and long-term follow-up of 17 patients.  J Korean Med Sci. 2006;  21 (2) 265-271
  CrossrefPubMedGoogle Scholar
• 35 de Souza F H, Radu Halpern A S, Valente Barbas C S, Shinjo S K. Wegener's granulomatosis: experience from a Brazilian tertiary center.  Clin Rheumatol. 2010;  29 (8) 855-860
  CrossrefPubMedGoogle Scholar
• 36 Flores-Suárez L F, Villa A R. Spectrum of Wegener granulomatosis in a Mexican population.  Ann N Y Acad Sci. 2007;  1107 400-409
  CrossrefPubMedGoogle Scholar
• 37 Fujimoto S, Uezono S, Hisanaga S et al.. Incidence of ANCA-associated primary renal vasculitis in the Miyazaki Prefecture: the first population-based, retrospective, epidemiologic survey in Japan.  Clin J Am Soc Nephrol. 2006;  1 (5) 1016-1022
  CrossrefPubMedGoogle Scholar
• 38 Teague C A, Doak P B, Simpson I J, Rainer S P, Herdson P B. Goodpasture's syndrome: an analysis of 29 cases.  Kidney Int. 1978;  13 (6) 492-504
  CrossrefPubMedGoogle Scholar
• 39 Watts R A, Scott D G, Jayne D R et al.. Renal vasculitis in Japan and the UK—are there differences in epidemiology and clinical phenotype?.  Nephrol Dial Transplant. 2008;  23 (12) 3928-3931
  CrossrefPubMedGoogle Scholar
• 40 Knight A, Sandin S, Askling J. Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease.  Arthritis Rheum. 2008;  58 (1) 302-307
  CrossrefPubMedGoogle Scholar
• 41 Knight A, Sandin S, Askling J. Increased risk of autoimmune disease in families with Wegener's granulomatosis.  J Rheumatol. 2010;  37 (12) 2553-2558
  CrossrefPubMedGoogle Scholar
• 42 Phelps R G, Rees A J. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity.  Kidney Int. 1999;  56 (5) 1638-1653
  CrossrefPubMedGoogle Scholar
• 43 Heckmann M, Holle J U, Arning L et al.. The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping.  Ann Rheum Dis. 2008;  67 (7) 972-979
  PubMedGoogle Scholar
• 44 Jagiello P, Gencik M, Arning L et al.. New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes.  Hum Genet. 2004;  114 (5) 468-477
  CrossrefPubMedGoogle Scholar
• 45 Vaglio A, Martorana D, Maggiore U Secondary and Primary Vasculitis Study Group et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome.  Arthritis Rheum. 2007;  56 (9) 3159-3166
  CrossrefPubMedGoogle Scholar
• 46 Wieczorek S, Hellmich B, Gross W L, Epplen J T. Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio et al.  Arthritis Rheum. 2008;  58 (1) 329-330
  CrossrefPubMedGoogle Scholar
• 47 Tsuchiya N, Kobayashi S, Hashimoto H, Ozaki S, Tokunaga K. Association of HLA-DRB1*0901-DQB1*0303 haplotype with microscopic polyangiitis in Japanese.  Genes Immun. 2006;  7 (1) 81-84
  CrossrefPubMedGoogle Scholar
• 48 Esnault V L, Testa A, Audrain M et al.. Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis.  Kidney Int. 1993;  43 (6) 1329-1332
  CrossrefPubMedGoogle Scholar
• 49 Mahr A D, Neogi T, Merkel P A. Epidemiology of Wegener's granulomatosis: Lessons from descriptive studies and analyses of genetic and environmental risk determinants.  Clin Exp Rheumatol. 2006;  24 (2, suppl 41) S82-S91
  PubMedGoogle Scholar
• 50 Mahr A D, Edberg J C, Stone J H et al.. Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis.  Arthritis Rheum. 2010;  62 (12) 3760-3767
  CrossrefPubMedGoogle Scholar
• 51 Carr E J, Niederer H A, Williams J et al.. Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis.  BMC Med Genet. 2009;  10 121
  CrossrefPubMedGoogle Scholar
• 52 Jagiello P, Aries P, Arning L et al.. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis.  Arthritis Rheum. 2005;  52 (12) 4039-4043
  CrossrefPubMedGoogle Scholar
• 53 Holle J U, Wieczorek S, Gross W L. Genetic association studies in ANCA-associated vasculitides: what we have learnt so far and what needs to be done in the future.  Clin Exp Rheumatol. 2010;  28 (1, suppl 57) 5-7
  PubMedGoogle Scholar
• 54 Wieczorek S, Hoffjan S, Chan A et al.. Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients.  Genes Immun. 2009;  10 (6) 591-595
  CrossrefPubMedGoogle Scholar
• 55 Giscombe R, Wang X, Huang D, Lefvert A K. Coding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener's granulomatosis.  J Rheumatol. 2002;  29 (5) 950-953
  PubMedGoogle Scholar
• 56 Slot M C, Sokolowska M G, Savelkouls K G, Janssen R G, Damoiseaux J G, Tervaert J W. Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis.  Clin Immunol. 2008;  128 (1) 39-45
  CrossrefPubMedGoogle Scholar
• 57 Spriewald B M, Witzke O, Wassmuth R et al.. Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis.  Ann Rheum Dis. 2005;  64 (3) 457-461
  PubMedGoogle Scholar
• 58 Zhou Y, Huang D, Paris P L, Sauter C S, Prock K A, Hoffman G S. An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis.  Arthritis Rheum. 2004;  50 (8) 2645-2650
  CrossrefPubMedGoogle Scholar
• 59 Hemminki K, Li X, Sundquist J, Sundquist K. Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions.  Arthritis Rheum. 2009;  60 (3) 661-668
  CrossrefPubMedGoogle Scholar
• 60 Mahr A, Artigues N, Coste J, Aouba A, Pagnoux C, Guillevin L. French Vasculitis Study Group . Seasonal variations in onset of Wegener's granulomatosis: increased in summer?.  J Rheumatol. 2006;  33 (8) 1615-1622
  PubMedGoogle Scholar
• 61 Kain R, Exner M, Brandes R et al.. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis.  Nat Med. 2008;  14 (10) 1088-1096
  CrossrefPubMedGoogle Scholar
• 62 Nuyts G D, Van Vlem E, De Vos A et al.. Wegener granulomatosis is associated to exposure to silicon compounds: a case-control study.  Nephrol Dial Transplant. 1995;  10 (7) 1162-1165
  PubMedGoogle Scholar
• 63 Hogan S L, Cooper G S, Savitz D A et al.. Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study.  Clin J Am Soc Nephrol. 2007;  2 (2) 290-299
  CrossrefPubMedGoogle Scholar
• 64 Gregorini G, Ferioli A, Donato F et al.. Association between silica exposure and necrotizing crescentic glomerulonephritis with p-ANCA and anti-MPO antibodies: a hospital-based case-control study.  Adv Exp Med Biol. 1993;  336 435-440
  PubMedGoogle Scholar
• 65 Beaudreuil S, Lasfargues G, Lauériere L et al.. Occupational exposure in ANCA-positive patients: a case-control study.  Kidney Int. 2005;  67 (5) 1961-1966
  CrossrefPubMedGoogle Scholar
• 66 Parks C G, Conrad K, Cooper G S. Occupational exposure to crystalline silica and autoimmune disease.  Environ Health Perspect. 1999;  107 (suppl 5) 793-802
  CrossrefPubMedGoogle Scholar
• 67 Duna G F, Cotch M F, Galperin C, Hoffman D B, Hoffman G S. Wegener's granulomatosis: role of environmental exposures.  Clin Exp Rheumatol. 1998;  16 (6) 669-674
  PubMedGoogle Scholar
• 68 Albert D, Clarkin C, Komoroski J, Brensinger C M, Berlin J A. Wegener's granulomatosis: possible role of environmental agents in its pathogenesis.  Arthritis Rheum. 2004;  51 (4) 656-664
  CrossrefPubMedGoogle Scholar
• 69 Knight A, Sandin S, Askling J. Occupational risk factors for Wegener's granulomatosis: a case-control study.  Ann Rheum Dis. 2010;  69 (4) 737-740
  CrossrefPubMedGoogle Scholar
• 70 Cuadrado M J, D'Cruz D, Lloyd M, Mujic F, Khamashta M A, Hughes G R. Allergic disorders in systemic vasculitis: a case-controlled study.  Br J Rheumatol. 1994;  33 (8) 749-753
  CrossrefPubMedGoogle Scholar
• 71 Haubitz M, Woywodt A, de Groot K, Haller H, Goebel U. Smoking habits in patients diagnosed with ANCA associated small vessel vasculitis.  Ann Rheum Dis. 2005;  64 (10) 1500-1502
  CrossrefPubMedGoogle Scholar
• 72 Mohammad A J, Segelmark M. Association of cigarette smoking with organ damage in primary systemic vasculitis.  Scand J Rheumatol. 2011;  40 (1) 51-56
  CrossrefPubMedGoogle Scholar
• 73 Gao Y, Zhao M H, Guo X H, Xin G, Gao Y, Wang H Y. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism.  Endocr Res. 2004;  30 (2) 205-213
  CrossrefPubMedGoogle Scholar
• 74 Gunton J E, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication.  Eur J Endocrinol. 2000;  142 (6) 587
  CrossrefPubMedGoogle Scholar
• 75 Harper L, Chin L, Daykin J et al.. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease.  Clin Endocrinol (Oxf). 2004;  60 (6) 671-675
  CrossrefPubMedGoogle Scholar
• 76 Sera N, Ashizawa K, Ando T et al.. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease.  Thyroid. 2000;  10 (7) 595-599
  CrossrefPubMedGoogle Scholar
• 77 Slot M C, Links T P, Stegeman C A, Tervaert J W. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: a long-term follow-up study.  Arthritis Rheum. 2005;  53 (1) 108-113
  CrossrefPubMedGoogle Scholar
• 78 Wada N, Mukai M, Kohno M, Notoya A, Ito T, Yoshioka N. Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole.  Endocr J. 2002;  49 (3) 329-334
  CrossrefPubMedGoogle Scholar
• 79 Zhao M H, Chen M, Gao Y, Wang H Y. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis.  Kidney Int. 2006;  69 (8) 1477-1481
  PubMedGoogle Scholar
• 80 Lionaki S, Hogan S L, Falk R J et al.. Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study.  Nephrol Dial Transplant. 2007;  22 (12) 3508-3515
  CrossrefPubMedGoogle Scholar
• 81 Hauser T, Mahr A, Metzler C et al.. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study.  Thorax. 2008;  63 (8) 677-682
  CrossrefPubMedGoogle Scholar
• 82 Harrold L R, Patterson M K, Andrade S E et al.. Asthma drug use and the development of Churg-Strauss syndrome (CSS).  Pharmacoepidemiol Drug Saf. 2007;  16 (6) 620-626
  CrossrefPubMedGoogle Scholar
• 83 Jennette J C, Falk R J, Andrassy K et al.. Nomenclature of systemic vasculitides: proposal of an international consensus conference.  Arthritis Rheum. 1994;  37 (2) 187-192
  CrossrefPubMedGoogle Scholar
• 84 Watts R, Lane S, Hanslik T et al.. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.  Ann Rheum Dis. 2007;  66 (2) 222-227
  PubMedGoogle Scholar
• 85 Hunder G G, Arend W P, Bloch D A et al.. The American College of Rheumatology 1990 criteria for the classification of vasculitis: introduction.  Arthritis Rheum. 1990;  33 (8) 1065-1067
  PubMedGoogle Scholar
• 86 Zhou Y, Giscombe R, Huang D, Lefvert A K. Novel genetic association of Wegener's granulomatosis with the interleukin 10 gene.  J Rheumatol. 2002;  29 (2) 317-320
  PubMedGoogle Scholar
• 87 Bártfai Z, Gaede K I, Russell K A, Muraközy G, Müller-Quernheim J, Specks U. Different gender-associated genotype risks of Wegener's granulomatosis and microscopic polyangiitis.  Clin Immunol. 2003;  109 (3) 330-337
  CrossrefPubMedGoogle Scholar
• 88 Wieczorek S, Hellmich B, Arning L et al.. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis.  Arthritis Rheum. 2008;  58 (6) 1839-1848
  CrossrefPubMedGoogle Scholar

Alfred MahrM.D. 

Department of Internal Medicine, Hospital Saint-Louis, University Paris 7–Paris Diderot, Assistance Publique–Hôpitaux de Paris, 1, avenue Claude-Vellefaux

75475 Paris Cedex 10, France

Email: alfred.mahr@sls.aphp.fr